Immutep and the Australian biotech’s investors have been caught off guard by the unexpected failure of its LAG-3 candidate in ...
Zacks Investment Research on MSN
Can Merck's new drugs & pipeline ease Keytruda LOE concerns?
Merck MRK is focusing on driving long-term growth through the newer products and a promising set of pipelines as its ...
Clinical Trials Arena on MSN
Immutep’s LAG-3 hopes take a hit on Phase III NSCLC termination
The company will now assess the available data to determine its next steps in progressing efti’s development across multiple ...
Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss. Improving distant control of lung cancer is the most exciting potential benefit of combining ...
The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?
Five-year exploratory follow-up analysis of KEYNOTE-671 continued to show clinically meaningful improvements in overall survival and event-free survival with KEYTRUDA plus chemotherapy before surgery, ...
Clinical Trials Arena on MSN
MSD announces results from Keytruda combination trial for RCC
The trial enrolled 1,841 patients and measured DFS, with safety, OS, and quality of life as secondary endpoints.
KEYTRUDA and KEYTRUDA QLEX are the first and only PD-1 inhibitors approved for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma with PD-L1+ tumors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results